So my name is Doris Hansen from the Health Health Cancer Center. Today we'll be discussing a bit about the cost per responder analysis among venividomide refractory multiple myeloma patients treated with Celtosol and Cartitude IV. So Celtosol or Celtocarpagina autosuggestion was FDA approved in 2022 for patients with Celtosol and Cartitude IV. It has shown superior efficacy in comparison to physicians' choice of DBT versus PBT in terms of professional survival, response rate, as well as complete response. So the objective of our study was really to assess the true value of Celtosol versus physicians' choice, not only accounting for clinical effectiveness but also for the economic benefit of this therapy. So we essentially set out to perform a cost per responder model. We used a mixed payer source, commercial and Medicare, to assess costs associated with this therapy, in particular costs associated with drug acquisition, aforesis, lymphatic lesion, cost, infusion cost, bridging cost, as well as management of toxicities, subsequent therapies, and prophylactic antibiotics. We created a model that compared total cost between Celtosol and physicians' choice. We also compared cost per complete responder and cost per month progression through survival over a 25-month period because that was the maximum time that a patient on physicians' choice remained on the treatment. And essentially we identified that the total cost was approximately seven versus $800,000 in Celtosol versus physicians' choice, cost per complete responder was a million versus nearly slightly over $3.5 million in Celtosol versus physicians' choice, and similarly the cost per month in PFS was approximately $30,000 versus $40,000 for Celtosol versus physicians' choice. So essentially seeing that in Celtosol there is economic benefit, particularly in patients who have complete response or better. We also did a scenario where 30% of patients were treated non-patients, which is a more common practice, especially in the large economic medical centers, and identified some of findings with economic benefit for Celtosol. So essentially we're hoping that our study will be helpful, particularly to payers in the sense that they are able to assess the true value of these novel immunotherapies when accounting for clinical benefit, but as well as economic benefit. And obviously our study did demonstrate that Celtosol is associated with significant benefits, not only clinically, but also an economic benefit for patients with relapsed refractory muscle problem. Thank you very much.
HealthTree • December 9, 2023